



Contact:

Dan Budwick  
BMC Communications Group, LLC  
973-271-6085  
dbudwick@bmccommunications.com

**SOPHERION THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW  
SENIOR EXECUTIVE VICE PRESIDENT FOR CLINICAL AFFAIRS**

Princeton, N.J., February 24, 2009 – Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozenzweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozenzweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

“I am excited to continue to contribute to the development of Myocet,” said Dr. Rozenzweig. “Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression.”

Dr. Rozenzweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

“Dr. Rozenzweig’s world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward,” said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. “His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol<sup>®</sup> and Paraplatin<sup>®</sup> (carboplatin).”

Dr. Rozenzweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

**About Sopherion Therapeutics, LLC**

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit [www.sopherion.com](http://www.sopherion.com).

# # #